<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00343460</url>
  </required_header>
  <id_info>
    <org_study_id>C2006-01</org_study_id>
    <secondary_id>APPA-C2006-01</secondary_id>
    <nct_id>NCT00343460</nct_id>
  </id_info>
  <brief_title>APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer</brief_title>
  <official_title>A Pivotal Phase 3 Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi For The Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea and Vomiting Following The Administration of Either Moderately or Highly Emetogenic Chemotherapy Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heron Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heron Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial is studying APF530 and dexamethasone to see how well they
      work compared with palonosetron and dexamethasone in preventing nausea and vomiting in
      patients receiving chemotherapy for cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the overall activity and effects of APF530 versus palonosetron hydrochloride in
           combination with dexamethasone for prophylaxis of acute- or delayed-onset,
           chemotherapy-induced nausea and vomiting in patients undergoing moderately or highly
           emetogenic chemotherapy for cancer.

      Secondary

        -  Evaluate the safety, tolerability, and efficacy of APF530, in terms of prevention of
           acute- and delayed-onset nausea and vomiting, in these patients.

        -  Gather the pharmacokinetics of APF530 in a subset of patients during chemotherapy course
           1.

        -  Gather ECG data (using 24-hour Holter monitoring) in a subset of patients during
           chemotherapy course 1.

      OUTLINE: This is a randomized, placebo-controlled, double-blind, parallel-group, multicenter
      study. Patients are stratified according to emetogenicity of scheduled chemotherapy
      (moderate-risk [level 3 or 4] vs high-risk [level 5]). Patients are randomized to 1 of 3
      treatment arms (I, II, and III). Patients who are randomized to receive palonosetron
      hydrochloride during chemotherapy course 1 (arm I) are then re-randomized to 1 of 2 treatment
      arms (II and III) after chemotherapy course 1 to receive treatment during chemotherapy
      courses 2-4.

      Patients receive palonosetron hydrochloride or APF530 and/or placebo 30-60 minutes before the
      start of chemotherapy. Patients receive dexamethasone 30-90 minutes before the start of
      chemotherapy.

        -  Arm I: Patients receive palonosetron hydrochloride IV, placebo subcutaneously (SC), and
           dexamethasone IV on day 1 of chemotherapy course 1. Patients in the high-risk (level 5)
           stratum also receive oral dexamethasone on days 2-4 of all treatment courses.

        -  Arm II: Patients receive APF530 SC, placebo IV, and dexamethasone IV on day 1 of
           chemotherapy course 1. Patients then receive APF530 SC and dexamethasone IV on day 1 of
           chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral
           dexamethasone as in arm I.

        -  Arm III: Patients receive APF530 SC at a higher dose, placebo IV, and dexamethasone IV
           on day 1 of chemotherapy course 1. Patients then receive APF530 SC (at the same higher
           dose) and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the
           high-risk (level 5) stratum also receive oral dexamethasone as in arm I.

      A subset of patients undergo blood collection periodically during study for analysis of
      plasma APF530 concentration.

      Quality of life is assessed on day 5 after completion of chemotherapy course 1.

      After completion of study treatment, patients are followed at approximately 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1</measure>
    <time_frame>0-24 Hours</time_frame>
    <description>Complete Response is defined as no emetic episodes and no use of rescue medications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1</measure>
    <time_frame>24-120 Hours</time_frame>
    <description>Complete Response is defined as no emetic episodes and no use of rescue medications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Complete Control During the Acute Phase (0-24 Hours), Delayed-onset Phase (24-120 Hours), and During Chemotherapy Course 1</measure>
    <time_frame>0-120 Hours</time_frame>
    <description>Complete control is defined as complete response with no more than mild nausea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Total Response During the Acute Phase, Delayed-onset Phase, and During Chemotherapy Course 1</measure>
    <time_frame>0-120 Hours</time_frame>
    <description>TR during acute phase is defined as Complete Response with no nausea during 0 to 24 hours following the administration of chemotherapy in Cycle 1.
TR during delayed-onset phase is defined as Complete Response with no nausea during &gt;24 to 120 hours following the administration of chemotherapy in Cycle 1. TR during overall risk period is defined as Complete Response with no nausea during 0 to 120 hours following the administration of chemotherapy in Cycle 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Emetic Episodes</measure>
    <time_frame>Days 1-5</time_frame>
    <description>Number of Emetic Episodes - days 1-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Treatment Failure</measure>
    <time_frame>0-120 Hours</time_frame>
    <description>Proportions of subjects event free at 24, 48, 72, 96, and 120 hours after chemotherapy administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First and Overall Use of Rescue Medication</measure>
    <time_frame>0-120 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Nausea Daily and During Chemotherapy Course 1 (0-120 Hours)</measure>
    <time_frame>0-120 Hours</time_frame>
    <description>Maximum severity of nausea, days 1-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustainability of Antiemetic Effect of APF530 Over Multiple Chemotherapy Courses</measure>
    <time_frame>0-120 Hours</time_frame>
    <description>Sustainability of Overall Complete Response (CR 0-120 hrs) Over Two, Three, and Four Cycles
Complete Response is defined as no emetic episodes and no use of rescue medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life and the Impact of Nausea and Vomiting on Day 5</measure>
    <time_frame>5 days</time_frame>
    <description>Functional Living Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Satisfaction With Antiemetic Therapy During Acute Phase and Chemotherapy Course 1</measure>
    <time_frame>0- 24 Hours</time_frame>
    <description>Subject who were very satisfied on Day 1</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1428</enrollment>
  <condition>Nausea and Vomiting</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive palonosetron hydrochloride IV, placebo subcutaneously (SC), and dexamethasone IV on day 1 of chemotherapy course 1. Patients in the high-risk (level 5) stratum also receive oral dexamethasone on days 2-4 of all treatment courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive APF530 SC, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive APF530 SC at a higher dose, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC (at the same higher dose) and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APF530</intervention_name>
    <description>Given subcutanously</description>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given IV and orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given subcutanously or IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed malignant disease

               -  No head and neck cancer or upper gastrointestinal cancer

          -  Scheduled to receive a single day of moderately or highly emetogenic chemotherapy
             regimen (for ≤ 4 courses)

               -  Chemotherapy administration ≤ 4 hours

               -  Duration of each course ≤ 28 days

               -  Causing nausea and vomiting in 30-100% of patients if untreated according to
                  Hesketh algorithm

          -  Must be able to receive standardized doses of dexamethasone for the prevention of
             emesis during study treatment

          -  No greater than mild nausea or any vomiting within 24 hours before beginning study
             treatment

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No known allergy or hypersensitivity to other selective 5-HT3 receptor antagonists or
             local anesthetics

          -  QTc interval ≤ 500 ms

          -  No cardiac abnormality predisposing the patient to arrhythmia

          -  No psychological problem that, in the opinion of the investigator, is severe enough to
             preclude study participation

          -  No recent history (i.e., ≤ 1 year) of alcohol or drug abuse

          -  No concurrent condition that, in the opinion of the investigator, could affect
             assessment of study medication or interfere with the nausea/vomiting response (e.g.,
             severe renal or hepatic impairment)

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No radiotherapy 7 days prior to, during, and 5 days after completion of study
             treatment

          -  More than 7 days since prior chemotherapy

          -  More than 7 days since prior and no concurrent prohibited medications (e.g., CYP3A4
             inhibitors or other antiemetic medications)

          -  More than 7 days since prior antinausea medications

          -  More than 30 days since prior treatment on an investigational trial

          -  No other concurrent corticosteroids or dexamethasone at a different dose than study
             treatment

          -  No concurrent use of APF530, palonosetron hydrochloride, or aprepitant as rescue
             medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Barr, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Heron Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anniston Oncology, PC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palo Verde Hematology Oncology - Glendale</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Clinical Research Center, Incorporated</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Cancer Research Center at University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center, Incorporated</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southbay Oncology / Hematology Medical Group</name>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Cancer Care Medical Group Incorporated - Corona</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Cancer Care Medical Group Incorporated - Fountain Valley</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Management Services, Incorporated</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenmar Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Care Associates - Orange</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Connecticut Hematology and Oncology Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pasco Pinellas Cancer Center - New Port Richey</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34689</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Medical Research of South Florida, Incorporated</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33179-4709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Clinic, PC</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clintell, Incorporated</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Clinical Research, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Indiana</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Medicine of Vincennes Clinical Trial Center</name>
      <address>
        <city>Vincennes</city>
        <state>Indiana</state>
        <zip>47591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Vincennes</name>
      <address>
        <city>Vincennes</city>
        <state>Indiana</state>
        <zip>47591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Cancer Clinic - Hazard</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentuckiana Cancer Institute, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Medical Oncology Associates at Central Maine Comprehensive Cancer Center</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202-2165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders at Suburban Hospital</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research at Washington County Hospital</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Hospital</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Center at Singing River Hospital</name>
      <address>
        <city>Pascagoula</city>
        <state>Mississippi</state>
        <zip>39581</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Centers - South</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Star Hematology &amp; Oncology</name>
      <address>
        <city>Phillipsburg</city>
        <state>New Jersey</state>
        <zip>08865</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Falck Cancer Center at Arnot Ogden Medical Center</name>
      <address>
        <city>Elmira</city>
        <state>New York</state>
        <zip>14905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudson Valley Hematology-Oncology Associates - Poughkeepsie</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Pardee Hospital</name>
      <address>
        <city>Hendersonville</city>
        <state>North Carolina</state>
        <zip>28791</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boice Willis Clinic, PA</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern North Carolina Medical Group, PLLC</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McDowell Cancer Center at Akron General Medical Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center - Canton Office</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center - Dover Office</name>
      <address>
        <city>Dover</city>
        <state>Ohio</state>
        <zip>44622</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedCentral - Mansfield Hospital</name>
      <address>
        <city>Mansfield</city>
        <state>Ohio</state>
        <zip>44903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Signal Point Hematology Oncology Incorporated</name>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <zip>45042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America at Southwestern Regional Medical Center</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133-4564</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pottsville Cancer Clinic</name>
      <address>
        <city>Pottsville</city>
        <state>Pennsylvania</state>
        <zip>17901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology Oncology Associates, PA</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julie and Ben Rogers Cancer Institute at Memorial Hermann Baptist Beaumont Hospital</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Clinic</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Outreach Associates - Abingdon</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Care, PC</name>
      <address>
        <city>Richlands</city>
        <state>Virginia</state>
        <zip>24641</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Washington Oncology, Incorporated, PS at Western Washington Cancer Center</name>
      <address>
        <city>Lacey</city>
        <state>Washington</state>
        <zip>98503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Regional Cancer Center at Tacoma General Hospital</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Babb Randolph Cancer Center at West Virginia University Hospitals</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506-9300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2006</study_first_submitted>
  <study_first_submitted_qc>June 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2006</study_first_posted>
  <results_first_submitted>September 9, 2016</results_first_submitted>
  <results_first_submitted_qc>October 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 28, 2016</results_first_posted>
  <last_update_submitted>February 10, 2017</last_update_submitted>
  <last_update_submitted_qc>February 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nausea and vomiting</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Granisetron</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>APF530 5 mg</title>
          <description>APF530 5 mg - Safety Population</description>
        </group>
        <group group_id="P2">
          <title>APF530 10 mg</title>
          <description>APF530 10 mg - Safety Population</description>
        </group>
        <group group_id="P3">
          <title>Aloxi 0.25 mg</title>
          <description>Aloxi 0.25 mg - Safety Population</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Cycle 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="475"/>
                <participants group_id="P2" count="481"/>
                <participants group_id="P3" count="472"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="453"/>
                <participants group_id="P2" count="459"/>
                <participants group_id="P3" count="454"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Cycle 2 - 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="584"/>
                <participants group_id="P2" count="565"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="528"/>
                <participants group_id="P2" count="515"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Modified Intent-to-Treat Population</population>
      <group_list>
        <group group_id="B1">
          <title>Cycle 1 APF530 5 mg - Moderately</title>
          <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
        </group>
        <group group_id="B2">
          <title>Cycle 1 APF530 10 mg - Moderately</title>
          <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
        </group>
        <group group_id="B3">
          <title>Cycle 1 Aloxi 0.25 mg - Moderately</title>
          <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
        </group>
        <group group_id="B4">
          <title>Cycle 1 APF530 5 mg - Highly</title>
          <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
        </group>
        <group group_id="B5">
          <title>Cycle 1 APF530 10 mg - Highly</title>
          <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
        </group>
        <group group_id="B6">
          <title>Cycle 1 Aloxi 0.25 Highly</title>
          <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="214"/>
            <count group_id="B2" value="212"/>
            <count group_id="B3" value="208"/>
            <count group_id="B4" value="229"/>
            <count group_id="B5" value="240"/>
            <count group_id="B6" value="238"/>
            <count group_id="B7" value="1341"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.8" spread="12.80"/>
                    <measurement group_id="B2" value="55.1" spread="12.79"/>
                    <measurement group_id="B3" value="57.3" spread="12.36"/>
                    <measurement group_id="B4" value="57.6" spread="13.35"/>
                    <measurement group_id="B5" value="56.8" spread="13.20"/>
                    <measurement group_id="B6" value="58.1" spread="13.74"/>
                    <measurement group_id="B7" value="56.62" spread="13.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="177"/>
                    <measurement group_id="B4" value="153"/>
                    <measurement group_id="B5" value="152"/>
                    <measurement group_id="B6" value="158"/>
                    <measurement group_id="B7" value="1006"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="76"/>
                    <measurement group_id="B5" value="88"/>
                    <measurement group_id="B6" value="80"/>
                    <measurement group_id="B7" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1</title>
        <description>Complete Response is defined as no emetic episodes and no use of rescue medications</description>
        <time_frame>0-24 Hours</time_frame>
        <population>Cycle 1 - Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cycle 1 APF530 5 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O2">
            <title>Cycle 1 APF530 10 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O3">
            <title>Cycle 1 Aloxi 0.25 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O4">
            <title>Cycle 1 APF530 5 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O5">
            <title>Cycle 1 APF530 10 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O6">
            <title>Cycle 1 Aloxi 0.25 Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1</title>
          <description>Complete Response is defined as no emetic episodes and no use of rescue medications</description>
          <population>Cycle 1 - Modified Intent-to-Treat Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
                <count group_id="O4" value="229"/>
                <count group_id="O5" value="240"/>
                <count group_id="O6" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="163"/>
                    <measurement group_id="O3" value="156"/>
                    <measurement group_id="O4" value="178"/>
                    <measurement group_id="O5" value="195"/>
                    <measurement group_id="O6" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1</title>
        <description>Complete Response is defined as no emetic episodes and no use of rescue medications</description>
        <time_frame>24-120 Hours</time_frame>
        <population>Cycle 1 - Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cycle 1 APF530 5 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O2">
            <title>Cycle 1 APF530 10 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O3">
            <title>Cycle 1 Aloxi 0.25 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O4">
            <title>Cycle 1 APF530 5 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O5">
            <title>Cycle 1 APF530 10 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O6">
            <title>Cycle 1 Aloxi 0.25 Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1</title>
          <description>Complete Response is defined as no emetic episodes and no use of rescue medications</description>
          <population>Cycle 1 - Modified Intent-to-Treat Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
                <count group_id="O4" value="229"/>
                <count group_id="O5" value="240"/>
                <count group_id="O6" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="120"/>
                    <measurement group_id="O4" value="148"/>
                    <measurement group_id="O5" value="164"/>
                    <measurement group_id="O6" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Complete Control During the Acute Phase (0-24 Hours), Delayed-onset Phase (24-120 Hours), and During Chemotherapy Course 1</title>
        <description>Complete control is defined as complete response with no more than mild nausea.</description>
        <time_frame>0-120 Hours</time_frame>
        <population>Cycle 1 - Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cycle 1 APF530 5 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O2">
            <title>Cycle 1 APF530 10 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O3">
            <title>Cycle 1 Aloxi 0.25 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O4">
            <title>Cycle 1 APF530 5 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O5">
            <title>Cycle 1 APF530 10 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O6">
            <title>Cycle 1 Aloxi 0.25 Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Complete Control During the Acute Phase (0-24 Hours), Delayed-onset Phase (24-120 Hours), and During Chemotherapy Course 1</title>
          <description>Complete control is defined as complete response with no more than mild nausea.</description>
          <population>Cycle 1 - Modified Intent-to-Treat Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
                <count group_id="O4" value="229"/>
                <count group_id="O5" value="240"/>
                <count group_id="O6" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CC during acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="147"/>
                    <measurement group_id="O4" value="170"/>
                    <measurement group_id="O5" value="183"/>
                    <measurement group_id="O6" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CC during the delayed-onset phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="115"/>
                    <measurement group_id="O3" value="107"/>
                    <measurement group_id="O4" value="138"/>
                    <measurement group_id="O5" value="150"/>
                    <measurement group_id="O6" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CC during the overall risk period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="127"/>
                    <measurement group_id="O5" value="138"/>
                    <measurement group_id="O6" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Total Response During the Acute Phase, Delayed-onset Phase, and During Chemotherapy Course 1</title>
        <description>TR during acute phase is defined as Complete Response with no nausea during 0 to 24 hours following the administration of chemotherapy in Cycle 1.
TR during delayed-onset phase is defined as Complete Response with no nausea during &gt;24 to 120 hours following the administration of chemotherapy in Cycle 1. TR during overall risk period is defined as Complete Response with no nausea during 0 to 120 hours following the administration of chemotherapy in Cycle 1.</description>
        <time_frame>0-120 Hours</time_frame>
        <population>Cycle 1 - Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cycle 1 APF530 5 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O2">
            <title>Cycle 1 APF530 10 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O3">
            <title>Cycle 1 Aloxi 0.25 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O4">
            <title>Cycle 1 APF530 5 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O5">
            <title>Cycle 1 APF530 10 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O6">
            <title>Cycle 1 Aloxi 0.25 Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Total Response During the Acute Phase, Delayed-onset Phase, and During Chemotherapy Course 1</title>
          <description>TR during acute phase is defined as Complete Response with no nausea during 0 to 24 hours following the administration of chemotherapy in Cycle 1.
TR during delayed-onset phase is defined as Complete Response with no nausea during &gt;24 to 120 hours following the administration of chemotherapy in Cycle 1. TR during overall risk period is defined as Complete Response with no nausea during 0 to 120 hours following the administration of chemotherapy in Cycle 1.</description>
          <population>Cycle 1 - Modified Intent-to-Treat Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
                <count group_id="O4" value="229"/>
                <count group_id="O5" value="240"/>
                <count group_id="O6" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TR during acute phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="121"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="141"/>
                    <measurement group_id="O5" value="146"/>
                    <measurement group_id="O6" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TR during the delayed-onset phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="115"/>
                    <measurement group_id="O5" value="113"/>
                    <measurement group_id="O6" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TR during the overall risk period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="103"/>
                    <measurement group_id="O5" value="101"/>
                    <measurement group_id="O6" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Emetic Episodes</title>
        <description>Number of Emetic Episodes - days 1-5</description>
        <time_frame>Days 1-5</time_frame>
        <population>Cycle 1 - Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cycle 1 APF530 5 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O2">
            <title>Cycle 1 APF530 10 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O3">
            <title>Cycle 1 Aloxi 0.25 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O4">
            <title>Cycle 1 APF530 5 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O5">
            <title>Cycle 1 APF530 10 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O6">
            <title>Cycle 1 Aloxi 0.25 Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Emetic Episodes</title>
          <description>Number of Emetic Episodes - days 1-5</description>
          <population>Cycle 1 - Modified Intent-to-Treat Population</population>
          <units>Number of Emetic Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="217"/>
                <count group_id="O5" value="236"/>
                <count group_id="O6" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="8.03"/>
                    <measurement group_id="O2" value="3.1" spread="9.35"/>
                    <measurement group_id="O3" value="2.1" spread="5.12"/>
                    <measurement group_id="O4" value="2.3" spread="6.69"/>
                    <measurement group_id="O5" value="2.4" spread="7.87"/>
                    <measurement group_id="O6" value="2.5" spread="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Treatment Failure</title>
        <description>Proportions of subjects event free at 24, 48, 72, 96, and 120 hours after chemotherapy administration</description>
        <time_frame>0-120 Hours</time_frame>
        <population>Proportions of subjects event free in Cycle 1 - Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cycle 1 APF530 5 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O2">
            <title>Cycle 1 APF530 10 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O3">
            <title>Cycle 1 Aloxi 0.25 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O4">
            <title>Cycle 1 APF530 5 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O5">
            <title>Cycle 1 APF530 10 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O6">
            <title>Cycle 1 Aloxi 0.25 - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Treatment Failure</title>
          <description>Proportions of subjects event free at 24, 48, 72, 96, and 120 hours after chemotherapy administration</description>
          <population>Proportions of subjects event free in Cycle 1 - Modified Intent-to-Treat Population</population>
          <units>Proportion of subjects event free</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="211"/>
                <count group_id="O3" value="208"/>
                <count group_id="O4" value="228"/>
                <count group_id="O5" value="238"/>
                <count group_id="O6" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.738"/>
                    <measurement group_id="O2" value="0.763"/>
                    <measurement group_id="O3" value="0.755"/>
                    <measurement group_id="O4" value="0.781"/>
                    <measurement group_id="O5" value="0.811"/>
                    <measurement group_id="O6" value="0.803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.636"/>
                    <measurement group_id="O2" value="0.659"/>
                    <measurement group_id="O3" value="0.635"/>
                    <measurement group_id="O4" value="0.706"/>
                    <measurement group_id="O5" value="0.723"/>
                    <measurement group_id="O6" value="0.714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.533"/>
                    <measurement group_id="O2" value="0.564"/>
                    <measurement group_id="O3" value="0.567"/>
                    <measurement group_id="O4" value="0.649"/>
                    <measurement group_id="O5" value="0.685"/>
                    <measurement group_id="O6" value="0.672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.485"/>
                    <measurement group_id="O2" value="0.550"/>
                    <measurement group_id="O3" value="0.534"/>
                    <measurement group_id="O4" value="0.618"/>
                    <measurement group_id="O5" value="0.668"/>
                    <measurement group_id="O6" value="0.634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.485"/>
                    <measurement group_id="O2" value="0.540"/>
                    <measurement group_id="O3" value="0.529"/>
                    <measurement group_id="O4" value="0.600"/>
                    <measurement group_id="O5" value="0.647"/>
                    <measurement group_id="O6" value="0.620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>First and Overall Use of Rescue Medication</title>
        <time_frame>0-120 Hours</time_frame>
        <population>Cycle 1 - Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cycle 1 APF530 5 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O2">
            <title>Cycle 1 APF530 10 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O3">
            <title>Cycle 1 Aloxi 0.25 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O4">
            <title>Cycle 1 APF530 5 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O5">
            <title>Cycle 1 APF530 10 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O6">
            <title>Cycle 1 Aloxi 0.25 - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
        </group_list>
        <measure>
          <title>First and Overall Use of Rescue Medication</title>
          <population>Cycle 1 - Modified Intent-to-Treat Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
                <count group_id="O4" value="229"/>
                <count group_id="O5" value="240"/>
                <count group_id="O6" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Used Rescue Medication, 0-24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Used Rescue Medication, 24-120 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="60"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Used Rescue Medication, 0-120 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="71"/>
                    <measurement group_id="O5" value="45"/>
                    <measurement group_id="O6" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Nausea Daily and During Chemotherapy Course 1 (0-120 Hours)</title>
        <description>Maximum severity of nausea, days 1-5</description>
        <time_frame>0-120 Hours</time_frame>
        <population>Severity of Nausea - Cycle 1 - Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cycle 1 APF530 5 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O2">
            <title>Cycle 1 APF530 10 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O3">
            <title>Cycle 1 Aloxi 0.25 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O4">
            <title>Cycle 1 APF530 5 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O5">
            <title>Cycle 1 APF530 10 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O6">
            <title>Cycle 1 Aloxi 0.25 - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Nausea Daily and During Chemotherapy Course 1 (0-120 Hours)</title>
          <description>Maximum severity of nausea, days 1-5</description>
          <population>Severity of Nausea - Cycle 1 - Modified Intent-to-Treat Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="219"/>
                <count group_id="O5" value="235"/>
                <count group_id="O6" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="105"/>
                    <measurement group_id="O5" value="102"/>
                    <measurement group_id="O6" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="53"/>
                    <measurement group_id="O5" value="68"/>
                    <measurement group_id="O6" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustainability of Antiemetic Effect of APF530 Over Multiple Chemotherapy Courses</title>
        <description>Sustainability of Overall Complete Response (CR 0-120 hrs) Over Two, Three, and Four Cycles
Complete Response is defined as no emetic episodes and no use of rescue medications</description>
        <time_frame>0-120 Hours</time_frame>
        <population>Number of subjects in the Modified Intent-to-Treat Population with overall CR (0-120 hrs) in all cycles</population>
        <group_list>
          <group group_id="O1">
            <title>Cycles 1, 2, 3 and 4 - Moderately</title>
            <description>APF530 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Cycles 1, 2, 3, and 4 - Moderately</title>
            <description>APF530 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Cycles 1, 2, 3 and 4 - Highly</title>
            <description>APF530 5 mg</description>
          </group>
          <group group_id="O4">
            <title>Cycles 1, 2, 3, and 4 - Highly</title>
            <description>APF530 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Sustainability of Antiemetic Effect of APF530 Over Multiple Chemotherapy Courses</title>
          <description>Sustainability of Overall Complete Response (CR 0-120 hrs) Over Two, Three, and Four Cycles
Complete Response is defined as no emetic episodes and no use of rescue medications</description>
          <population>Number of subjects in the Modified Intent-to-Treat Population with overall CR (0-120 hrs) in all cycles</population>
          <units>participants with overall CR</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life and the Impact of Nausea and Vomiting on Day 5</title>
        <description>Functional Living Index</description>
        <time_frame>5 days</time_frame>
        <population>Cycle 1 - Modified Intent-to-Treat Population (All Languages Except Punjabi)</population>
        <group_list>
          <group group_id="O1">
            <title>Cycle 1 APF530 5 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O2">
            <title>Cycle 1 APF530 10 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O3">
            <title>Cycle 1 Aloxi 0.25 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O4">
            <title>Cycle 1 APF530 5 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O5">
            <title>Cycle 1 APF530 10 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O6">
            <title>Cycle 1 Aloxi 0.25 - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life and the Impact of Nausea and Vomiting on Day 5</title>
          <description>Functional Living Index</description>
          <population>Cycle 1 - Modified Intent-to-Treat Population (All Languages Except Punjabi)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="223"/>
                <count group_id="O5" value="228"/>
                <count group_id="O6" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No nausea impact on daily life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="127"/>
                    <measurement group_id="O3" value="120"/>
                    <measurement group_id="O4" value="142"/>
                    <measurement group_id="O5" value="142"/>
                    <measurement group_id="O6" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No vomiting impact on daily life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="162"/>
                    <measurement group_id="O3" value="160"/>
                    <measurement group_id="O4" value="173"/>
                    <measurement group_id="O5" value="182"/>
                    <measurement group_id="O6" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Satisfaction With Antiemetic Therapy During Acute Phase and Chemotherapy Course 1</title>
        <description>Subject who were very satisfied on Day 1</description>
        <time_frame>0- 24 Hours</time_frame>
        <population>Cycle 1 - Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cycle 1 APF530 5 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O2">
            <title>Cycle 1 APF530 10 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O3">
            <title>Cycle 1 Aloxi 0.25 mg - Moderately</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Moderately</description>
          </group>
          <group group_id="O4">
            <title>Cycle 1 APF530 5 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O5">
            <title>Cycle 1 APF530 10 mg - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
          <group group_id="O6">
            <title>Cycle 1 Aloxi 0.25 - Highly</title>
            <description>Cycle 1 - Modified Intent-to-Treat Population
Emetogenic Status: Highly</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Satisfaction With Antiemetic Therapy During Acute Phase and Chemotherapy Course 1</title>
          <description>Subject who were very satisfied on Day 1</description>
          <population>Cycle 1 - Modified Intent-to-Treat Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
                <count group_id="O4" value="229"/>
                <count group_id="O5" value="240"/>
                <count group_id="O6" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="113"/>
                    <measurement group_id="O3" value="98"/>
                    <measurement group_id="O4" value="128"/>
                    <measurement group_id="O5" value="128"/>
                    <measurement group_id="O6" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cycle 1 APF530 5 mg</title>
          <description>Serious Treatment-Emergent Adverse Events - Cycle 1 - Safety Population</description>
        </group>
        <group group_id="E2">
          <title>Cycle 1 APF530 10 mg</title>
          <description>Serious Treatment-Emergent Adverse Events - Cycle 1 - Safety Population</description>
        </group>
        <group group_id="E3">
          <title>Cycle 1 Aloxi 0.25 mg</title>
          <description>Serious Treatment-Emergent Adverse Events - Cycle 1 - Safety Population</description>
        </group>
        <group group_id="E4">
          <title>Cycles 2-4 APF530 5 mg</title>
          <description>Serious Treatment-Emergent Adverse Events - Cycles 2-4 - Safety Population</description>
        </group>
        <group group_id="E5">
          <title>Cycle 2-4 APF530 10 mg</title>
          <description>Serious Treatment-Emergent Adverse Events - Cycles 2-4 - Safety Population</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="73" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Prothrombin level abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Appendicectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Tumour excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Septic phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="335" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="349" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="313" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="422" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="413" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="86" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="87" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="78" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="79" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="69" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="66" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="73" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="80" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="94" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="124" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="153" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="61" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="90" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="515"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="464"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="468"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="82" subjects_at_risk="528"/>
                <counts group_id="E5" subjects_affected="69" subjects_at_risk="515"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A period of 60 working days for presentational material and abstracts and 90 days for manuscripts is permitted for the sponsor's review. The sponsor can request modifications of any manuscript or other materials to be published or presented. The sponsor can also request additional time to obtain additional patent protection or take such other measures to establish and preserve its intellectual property and proprietary rights before publishing information from this trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Geller, M.D.</name_or_title>
      <organization>Heron Therapeutics</organization>
      <phone>650-366-2626</phone>
      <email>rgeller@herontx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

